We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Sets Feb. 5 Date for Avastin’s Colon Cancer sBLA
FDA Sets Feb. 5 Date for Avastin’s Colon Cancer sBLA
October 19, 2012
The FDA has granted a priority review to Genentech’s sBLA for Avastin in people with metastatic colorectal cancer (mCRC) who have already been treated with chemotherapy plus Avastin.